Qingxiu Dang1, Hong Zhou1, Juan Qian1, Li Yang1, Jianfei Huang2, Yaping Zhang3, Wenyu Shi4. 1. Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China. 2. Clinical Biobank, Department of Pathology, Affiliated Hospital of Nantong University, Nantong, China. 3. Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China. Electronic address: zzyaping@163.com. 4. Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China. Electronic address: shiwenyu@hotmail.com.
Abstract
INTRODUCTION: Lysosomal-associated membrane protein 1 (LAMP1) is a lysosomal and plasma membrane protein that contributes to tumor metastatic potential and differentiation. PATIENTS AND METHODS: We performed immunohistochemical staining to investigate LAMP1 protein expression levels in 122 diffuse large B-cell lymphoma (DLBCL) tumor samples and 45 reactive hyperplasia tissues. Correlations between LAMP1 expression, various clinicopathologic features, and patient prognosis were evaluated by univariate and multivariate analyses. RESULTS: LAMP1 expression was greater in the DLBCL tissues than in the reactive hyperplasia tissues. High LAMP1 expression was significantly associated with a high international prognostic index (score, 3-5; P = .023) and elevated lactate dehydrogenase level (P = .028). Moreover, high LAMP1 expression (P = .026), elevated serum lactate dehydrogenase level (P = .011), and high international prognostic index (P < .001) were independently associated with worse overall survival and progression-free survival. CONCLUSION: These data provide the first evidence that LAMP1 expression is associated with a poor prognosis in patients with DLBCL.
INTRODUCTION:Lysosomal-associated membrane protein 1 (LAMP1) is a lysosomal and plasma membrane protein that contributes to tumor metastatic potential and differentiation. PATIENTS AND METHODS: We performed immunohistochemical staining to investigate LAMP1 protein expression levels in 122 diffuse large B-cell lymphoma (DLBCL) tumor samples and 45 reactive hyperplasia tissues. Correlations between LAMP1 expression, various clinicopathologic features, and patient prognosis were evaluated by univariate and multivariate analyses. RESULTS:LAMP1 expression was greater in the DLBCL tissues than in the reactive hyperplasia tissues. High LAMP1 expression was significantly associated with a high international prognostic index (score, 3-5; P = .023) and elevated lactate dehydrogenase level (P = .028). Moreover, high LAMP1 expression (P = .026), elevated serum lactate dehydrogenase level (P = .011), and high international prognostic index (P < .001) were independently associated with worse overall survival and progression-free survival. CONCLUSION: These data provide the first evidence that LAMP1 expression is associated with a poor prognosis in patients with DLBCL.